Boston, MA 03/25/2014 (wallstreetpr) – Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) hopes to zero in with a medical solution in a market segment where many developers have shied away from. The company is developing Ebola medication and this month the U.S. Food and Drug Administration – FDA, granted fast-track designation to its drug candidate targeting Ebola virus. The company started human trial of its Ebola drug in January, having noted encouraging results in other animals. The fast-track designation is granted to promising experimental drugs with potential of filling gap in the unmet medical need areas. Ebola is an infectious and one of the most dangerous diseases with as much as 90 percent fatality rate according WHO. However, while the disease emerged about 40 years ago in the jungle pockets of Africa, drug developers seemed to lack interest in the segment given that the disease has rare outbreaks and it is often confined to the rural poor pockets of Africa. But all the same, Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) is pushing ahead with its Ebola drug development and hopes that it will be a rewarding effort at the end of the day.
Plug Power Inc (NASDAQ:PLUG) shares continue to benefit from the hype around fuel cells stock in which PLUG is a leading figure. The company, though unprofitable, is starting to win over big commercial customers for its alternative fuel solutions. Last year revenue in the company came in at $26.6 million and revenue is projected to total $65 million in the current fiscal year. The alternative clean energy which the company provides involves electricity generated through a chemical reaction of natural gas or hydrogen. The alternative energy is being adopted in industrial equipments like forklifts as it is considered efficient and clean. Shares of Plug Power Inc (NASDAQ:PLUG) soared about 3,000 percent in the past year.
SMART Technologies Inc (NASDAQ:SMT) shares are up today on the back of positive price objective adjustment which analysts at CIBC issued on the stock. The analysts raised their price target on the stock from $4.50 to $6.50. Compared with the previous closing price of the stock, the new price target suggests upside potential of more than 76 percent. The stock of SMT has witnessed positive estimates in the recent times, thus it bears consensus “buy” recommendation. However, its average price target of $3.82 suggests potential downside from the stock’s prevailing price.
